Prof. Ugur Sahin, M.D.

Ugur Sahin was born in Turkey and moved to Germany at age four, growing up in Cologne. He studied medicine at the University of Cologne, completing a doctoral thesis in cancer immunotherapy. He remained in academia as an oncohematology physician and researcher at university hospitals in Saarland and Zurich before establishing a research group at the University of Mainz in 2000 and becoming a professor of experimental oncology in 2006. In 2001, he co-founded Ganymed Pharmaceuticals with Ozlem Tureci and Christoph Huber, developing the monoclonal antibody zolbetuximab for gastrointestinal cancer. Ganymed was sold to Astellas Pharma in 2016 for over $436 million after demonstrating significant survival benefit in gastric cancer. Sahin's defining founding philosophy was the conviction that cancer treatment must be individualized because each patient's tumor is genetically unique—an insight developed through years of clinical practice watching standardized therapies fail.

BioNTech (Biopharmaceutical New Technologies) was founded in 2008 in Mainz, Germany, by a husband-and-wife team of physicians and brilliant scientists: Uğur Şahin and Özlem Türeci, along with Austrian oncologist Christoph Huber. Şahin and Türeci are the children of Turkish immigrants who moved to Germany in the 1960s. They met while working at an university hospital in Homburg, bonding over a shared, obsessive dedication to cancer research (famously spending their wedding day in the laboratory). The foundational vision of BioNTech was radically different from traditional oncology. While pharmaceutical companies were focused on creating blockbuster cancer drugs (chemicals designed to kill tumors broadly, often with horrific side effects), Şahin and Türeci believed that cancer was a personalized disease. Every patient's tumor had an unique genetic mutation. Therefore, the cure had to be personalized. Their goal was to use messenger RNA (mRNA) to instruct a patient's own immune system to recognize and destroy their specific, unique cancer cells. For over a decade, they labored in relative obscurity, constantly struggling to secure funding for their theoretical, unproven mRNA platform. In 2019, they finally took the company public on the NASDAQ, raising capital to fund their cancer trials. Just months later, in January 2020, Şahin read a medical journal article about a mysterious new respiratory virus in Wuhan, China. Recognizing the threat, he immediately initiated 'Project Lightspeed,' pivoting BioNTech's entire mRNA oncology platform toward designing a vaccine for the novel coronavirus over a single weekend. Partnering with Pfizer for global manufacturing and distribution, the founders' decades of obscure, unfunded research culminated in the delivery of a vaccine that saved millions of lives and instantly elevated them into the pantheon of the most consequential scientists in human history.